EADV 2026视频特辑｜Torello M. Lotti教授：慢性荨麻疹的新型疗法及PNEI机制

意大利古列尔莫・马可尼大学皮肤病学教授 Torello Lotti深度解析了慢性荨麻疹的前沿诊疗进展。

他基于对疾病致病通路的全新认知，系统介绍了多款处于研究前沿的创新疗法：包括靶向嗜酸性粒细胞、肥大细胞表面蛋白的 SIGLEC8 抑制剂，非 Th2/IgE 通路的 MRGPRX2 抑制剂，针对耐药位点的抗 CD23 单抗 UB221，布鲁顿酪氨酸激酶（BTK）抑制剂瑞米布替尼，以及靶向 KIT 受体的单抗药物。教授同时对比了上述新药与当前标准治疗方案（如奥马珠单抗）的作用差异，阐释了其能够覆盖的未满足临床需求。Lotti 教授提出了心理 - 神经 - 内分泌 - 免疫（PNEI）疾病模型的全新视角，解读神经肽对皮肤局部免疫的调控机制、雌激素在慢性荨麻疹中的双重作用，以及性别差异带来的治疗应答区别。

此外，Lotti 教授还探讨了近一年领域内的核心研究突破对未来临床治疗选择与疾病管理模式的影响，为慢性荨麻疹的个体化诊疗提供了前沿参考。

Torello Lotti, Professor of Dermatology at Guglielmo Marconi University in Italy, delivers an in-depth analysis of cutting-edge advances in the diagnosis and treatment of chronic urticaria.

Based on the latest understanding of the disease’s pathogenic pathways, he systematically presents multiple frontier innovative therapies: SIGLEC8 inhibitors targeting surface proteins on eosinophils and mast cells, MRGPRX2 inhibitors acting independently of the Th2/IgE pathway, the anti-CD23 monoclonal antibody UB221 directed at drug resistance-related sites, the Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib, and monoclonal antibody therapies targeting the KIT receptor. Professor Lotti also compares the mechanistic differences between these novel agents and current standard treatment regimens (such as omalizumab), and elaborates on the unmet clinical needs they are able to address.

Professor Lotti puts forward a novel perspective of the psycho-neuro-endocrine-immune (PNEI) disease model, interpreting the regulatory mechanism of neuropeptides on local skin immunity, the dual role of estrogens in chronic urticaria, and the disparities in treatment response caused by gender differences.

In addition, Professor Lotti discusses the impact of core research breakthroughs in the field over the past year on future clinical treatment choices and disease management patterns, providing cutting-edge reference for the individualized diagnosis and treatment of chronic urticaria.